✓ No active regulatory warningsFDA MedWatch, EMA EudraVigilance, WHO VigiBase, WADA Prohibited List · 2026-05-29
📰Read the full Saw Palmetto evidence review on GMJ News →Complete clinical article, references and updates on news.gmj.ge. This page is the structured safety summary.⚠ Patient using saw palmetto for BPH symptoms — STEP and CAMUS trials were negative [3]
⚠ Pregnant woman or woman of childbearing age — 5-AR inhibition is teratogenic [1]
⚠ Saw palmetto does NOT lower PSA — prostate cancer screening is unaffected [2]
⚠ Patient delaying evidence-based BPH treatment (finasteride, tamsulosin) in favor of saw palmetto — redirect [3]
ℹ️ Not obtained from food. Not applicable — this is not obtained from food in meaningful amounts; supplementation is the practical route.
🔬 Lab interpreter
Recommended test
PSA (prostate-specific antigen)
PSA (prostate-specific antigen)
Reference range / target
Per age-adjusted guidelines
Per age-adjusted guidelines
Unlike finasteride, saw palmetto does not lower PSA [2].
Full lab monitoring ↓⚕ For professionals — confirm ranges against your local laboratory.
Clinical verdict
Two definitive NIH trials (STEP, CAMUS) showed NO benefit of saw palmetto for BPH — even at 960 mg/day. Cochrane agrees. Despite this, it remains one of the best-selling supplements for prostate health. Does NOT affect PSA (unlike finasteride). CONTRAINDICATED in pregnancy (5-AR inhibition = teratogenic). If a patient insists on trying, the evidence says it won't work [3].
1 How much do I need?
👤 Adults: Specific dosage data under clinical review
👴 Elderly: Specific dosage data under clinical review
🤰 Pregnancy: See guidance
CONTRAINDICATED. 5-alpha-reductase inhibition is teratogenic. Avoid in pregnancy and women of childbearing potential [1].
👦 Pediatric: See guidance
Not appropriate for children [1].
🏃 Athletes: Standard dose
⚖️ Obesity: Standard dose
Fat-soluble compounds may require dose adjustment in obesity.
🩺 Renal: Consult specialist
Dose adjustment may be needed in renal impairment.
🌱 Vegan: Standard dose
How to take
🍽 Timing: 320 mg once daily or 160 mg BID with meals [2].
💊 With food: Take with food (fat enhances absorption of lipophilic extract) [2].
2 Which form?
| Form | Bioavailability | Vegan | Cost |
|---|---|---|---|
| ['Lipophilic extract (85–95% fatty acids)', 'common', 'Standard form used in clinical trials. Permixon (France) is the most studied brand. 320 mg/day [2].'] | Standard | Check label | |
| ['Supercritical CO₂ extract', 'preferred', 'Higher concentration of active fatty acids [2].'] | Standard | Check label | |
| ['Dried berry/powder', '', 'Non-standardized. Not recommended for therapeutic use [1].'] | Standard | Check label |
3 Common questions
Does saw palmetto work for BPH? ▼
Two rigorous NIH-funded trials (STEP and CAMUS) showed NO benefit over placebo, even at triple the standard dose [3]. Earlier European trials were positive, creating the market, but the definitive evidence is negative. The Cochrane review agrees.
Why do people still take it? ▼
Earlier positive trials, widespread marketing, and the appeal of a 'natural alternative' to pharmaceuticals maintain demand. Some individuals report subjective improvement, but this is consistent with placebo response (which was robust in trials) [3].
Is saw palmetto safer than finasteride? ▼
Saw palmetto has fewer sexual side effects than finasteride, but it also doesn't work for BPH [3]. Finasteride has strong evidence for BPH symptom reduction and prostate size reduction. The safety advantage is moot without efficacy.
Does saw palmetto affect PSA? ▼
No — unlike finasteride (which halves PSA), saw palmetto does NOT reduce PSA levels [2]. This means prostate cancer screening is not confounded by saw palmetto use, which is a practical advantage.
4 Clinical evidence
Strong
STEP trial (n=225): saw palmetto 320 mg/day showed NO improvement in AUASI scores vs placebo for BPH [3]. CAMUS trial (n=369): even at escalated doses up to 960 mg/day, no benefit was observed [3]. These are the definitive US trials. Does NOT reduce PSA (unlike finasteride) — important for cancer screening [2]. HIGH
Moderate
Earlier European trials (1990s–2000s): some showed modest LUTS improvement with Permixon extract. A Cochrane review concluded that saw palmetto does not improve urinary symptoms more than placebo [3]. Anti-inflammatory effects on prostatic tissue demonstrated histologically [2]. MODERATE
Insufficient
5 Safety, toxicity & adverse events
Relative
⚠ Concurrent hormonal therapy (finasteride, dutasteride) — additive 5α-reductase inhibition
⚠ Concurrent oral contraceptives or HRT — theoretical anti-androgenic interaction
⚠ May mask PSA levels — inform urologist before PSA testing
⚠ Concurrent anticoagulants — rare case reports of bleeding
🚩 Red flags
● Pregnant woman exposed to saw palmetto — teratogenic risk (5-AR inhibition) [1]
● Patient delaying urologist referral for worsening LUTS — saw palmetto is not effective treatment [3]
6 Interactions
Drug interactions
Finasteride/dutasteride Moderate
Mechanism: Additive 5-alpha-reductase inhibition. [2]
Effect: No proven additional benefit. May increase anti-androgenic side effects. [2]
Action: No rationale for combination. Use finasteride alone (evidence-based) [2].
Supplement synergies
Beta-sitosterol · 60–130 mg/day
Beta-sitosterol has slightly better evidence for LUTS than saw palmetto. Often combined [2].
Beta-sitosterol has slightly better evidence for LUTS than saw palmetto. Often combined [2].
7 Regulatory
United States (FDA): Dietary supplement. No drug approval. The FDA has not endorsed claims for BPH [1].
France: Permixon is a prescription drug for BPH (based on older European trials) [2].
Germany: Commission E approved for BPH stages I–II (based on pre-STEP/CAMUS data) [2].
South Korea: Available as dietary supplement.
8 US supplement products
332
on-market products containing Saw Palmetto (NIH DSLD)
Brands carrying Saw Palmetto (179)
Click a brand to see its Saw Palmetto products.
9 Frequently paired with
10 Cite this page
Vancouver: Pkhakadze G. Saw Palmetto — safety profile [Internet]. Tbilisi: PHIG; 2026 [cited 2026 Aug 15]. Available from: https://supplement.ge/ingredients/saw-palmetto/
APA 7th: Pkhakadze, G. (2026). Saw Palmetto — Safety profile. Public Health Institute of Georgia. https://supplement.ge/ingredients/saw-palmetto/
📋 Editorial information
Author: Prof. G. Pkhakadze, MD, MPH, PhD
Institution: Public Health Institute of Georgia (PHIG)
Affiliation: David Tvildiani Medical University (DTMU)
First published: January 2026
Last reviewed: 2026-05-29
Next review: February 2027
References: 3 cited sources
COI: SupplementIndex receives no funding from supplement manufacturers. All content independently authored by PHIG.
Process: Systematic literature review
📄 License & reuse
Published under Creative Commons Attribution 4.0 International (CC BY 4.0). You may share and adapt for any purpose with attribution.
Pkhakadze G. "Saw Palmetto — Safety Profile." SupplementIndex, PHIG, 2026. https://supplement.ge/ingredients/saw-palmetto/ CC BY 4.0.
GP
Prof. G. Pkhakadze, MD, MPH, PhD
Professor of Public Health · Head of Department, DTMU
Editor-in-Chief, Georgian Medical Journal (ISSN 3088-4322)
Chair, Public Health Institute of Georgia · UEMS Public Health Section
Educational and public health purposes. CC BY 4.0. Consult your healthcare provider before starting any supplement. Corrections: info@accreditation.ge. Publisher: PHIG